Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ERAS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Naporafenib | Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 · NCT06346067 | Active not recruiting |
| Vopimetostat | PDAC | Phase 1/2 · NCT07897734 | Not yet recruiting |
| Gilteritinib | Acute Myeloid Leukemia | Phase 1/2 · NCT05279859 | Withdrawn |
| SHP2 Inhibitor ERAS-601 | Advanced or Metastatic Solid Tumors | Phase 1/2 · NCT04866134 | Completed |
| ERK1/2 Inhibitor ERAS-007 | Advanced or Metastatic Solid Tumors | Phase 1/2 · NCT04866134 | Completed |
| Pan-RAS Molecular Glue ERAS-0015 | PDAC | Phase 1/2 · NCT07897734 | Not yet recruiting |
| EGFR Inhibitor ERAS-801 | Glioblastoma Multiforme | Phase 1 · NCT05222802 | Active not recruiting |
| Pan-KRAS Inhibitor ERAS-4001 | Metastatic Solid Tumors | Phase 1 · NCT07021898 | Recruiting |
| Osimertinib | Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 · NCT04959981 | Completed |
Also used in these trials (approved or third-party drugs, not ERAS's own candidates): Dacarbazine, Trametinib, Temozolomide, Cetuximab, Palbociclib, Encorafenib, Pembrolizumab, Sotorasib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ERAS holds $947.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $30M/quarter from operations, an estimated runway of 94.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ERAS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Jonathan E. Lim | 5%+ holder (13G) | 36,968,486 | 10.53% | 2026-06-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 22,446,754 | 6.40% | 2026-09-30 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 16,382,812 | 4.67% | 2026-03-31 |
| David M. Chacko CFO and CBO · +1.44M options |
Insider | 279,980 | 0.08% | 2025-12-15 |
| Pratik S Multani Director · +169,420 options |
Insider | 172,866 | 0.05% | 2025-05-23 |
| Ebun Garner Chief Legal Officer · +1.59M options |
Insider | 25,076 | 0.01% | 2026-04-01 |
Share count 350,956,416 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ERAS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →